Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. (Q53798598)

19 May 2018

title

Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. (English)

1 reference

19 May 2018

1 reference

8

Dominick J Angiolillo

1 reference

19 May 2018

author name string

Antonio Tello-Montoliu

1

1 reference

19 May 2018

Fabiana Rollini

2

1 reference

19 May 2018

Bhaloo Desai

3

1 reference

19 May 2018

Giuseppe Pasqualino

4

1 reference

19 May 2018

Ronakkumar Patel

5

1 reference

19 May 2018

Alexandra Santana Sorensen

6

1 reference

19 May 2018

Kjell S Sakariassen

7

1 reference

19 May 2018

publication date

1 October 2012

1 reference

19 May 2018

Journal of Thrombosis and Thrombolysis

published in

1 reference

19 May 2018

volume

34

1 reference

19 May 2018

issue

3

1 reference

19 May 2018

page(s)

297-299

1 reference

19 May 2018

Role of platelets and antiplatelet therapy in cardiovascular disease

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Prostanoid and isoprostanoid pathways in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Measurements of platelet interaction with components of the vessel wall in flowing blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Antiplatelet drug therapy: role of pharmacodynamic and genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Cyclooxygenase-2 expression and inhibition in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11239-012-0795-6

Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22923024

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22923024

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22923024

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11239-012-0795-6

1 reference

19 May 2018

1 reference

19 May 2018